-
Forward Look
Guiding Patients From Screening Through TreatmentPatient navigators can play an important role in cancer care.
by Alanna Kennedy-Gorman
-
Forward Look
Vitamin E and Cancer RiskStudies send mixed signals on potential benefits and harmful effects of vitamin E.
by Mitzi Baker
-
Cutting Cancer’s Engine
Renewed interest in research about metabolism, the process cells use to fuel their growth, could lead to new types of cancer treatments.
by Stephen Ornes
-
Missing the Mark
Only one-third of new cancer therapies or drug combinations tested in phase III clinical trials prove to be better than the standard of care. Researchers explain why and how they are aiming to improve the odds.
by Sue Rochman
-
Forward Look
Bridging the DistanceQ&A with medical oncologist Ana María López, medical director of the telemedicine program at the University of Arizona Cancer Center in Tucson.
by Sue Rochman
-
Forward Look
Treading Carefully With Medical ScansTo reduce your long-term cancer risk, make sure the tests are justified.
by Ingfei Chen
-
Forward Look
A Trojan Horse to Fight CancerAn experimental treatment shows the potential of a new family of targeted drugs.
by Stephen Ornes
-
Forward Look
Common-Sense ScreeningSigmoidoscopy may be a good option for colorectal cancer screening.
by Sue Rochman
-
Forward Look
Task Force Says “No” to PSA for Prostate Cancer ScreeningExpert panel's recommendation spurs debate.
by Stephen Ornes
-
A Genetic Legacy
Doctors now know more than ever about the inherited cancer-related mutations that can link generations of family members. But with the new knowledge from scientific advances and DNA testing come new questions for patients.
by Sue Rochman
Cancer Talk
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer
Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff
Cancer Today Editors’ Picks: 2024Our favorite Cancer Today stories from 2024, as picked by the editors.